logo
Want to help Georgia's sea turtles thrive? We talked to a few experts for some tips

Want to help Georgia's sea turtles thrive? We talked to a few experts for some tips

Yahoo03-07-2025
As of June 13, nearly 940 sea turtle nests had been identified along Georgia's coast. One egg from each of those nests has been split open and emptied into a test tube.
Don't fret. Each nest's clutch (the group term for reptile offspring) typically consists of 120 to 170 eggs. Every sacrificial embryo serves the greater purpose of tracking sea turtle ancestry. Biologists like Veterinary Tech Sarah Alley of the Tybee Island Marine Science Center catalogues the maternal DNA captured from eggs placed in the test tubes. The tubes are then passed on to the Mark Dodd, the sea turtle program coordinator for the Georgia Department of Natural Resources (DNR) Wildlife Conservation Section. He is a senior wildlife biologist who works with University of Georgia (UGA) Senior Research Scientist Brian Shamblin to compile the DNA and nesting data from the dozen members of the Georgia Sea Turtle Cooperative at Seaturtle.org.
All that data contributes to groups like the Caretta Research Project's tracking of turtles' migration patterns. A more recent collaboration between Caretta and the University of Florida is also closely examining what and where sea turtles eat.
As Caretta's Education and Outreach Coordinator Kristen Zemaitis explained, sea turtles play important roles in the broader oceanic food web. They can be a key indicator of ocean ecosystem health, which is why their preservation is crucial.
After concerning dips in sea turtle populations between the 1960s and early 1990s, concerted conservation efforts by the Cooperative over the last few decades have helped restore turtle numbers. More efforts can be done, however, even by the everyday beachgoer and tourist.
Before sea turtles obtained federal protections under the Endangered Species Act, Dodd said humans regularly poached eggs for protein or out of novelty. Sea turtle eggs must still contend with predators such as coyotes, wild boars, raccoons, seagulls and even burrowing Ghost Crabs, among others. The turtles themselves must evade sharks and other larger water-dwelling predators below surface before they ever even make it to sexual maturity, let alone come ashore to nest.
Human behaviors also still impact turtles. Everything from boat propellers to plastic pollution to, yes, even sandcastles can imperil turtles and their nesting habits.
All the experts interviewed for this story shared variations of these steps that anyone can take to assist ongoing conservation efforts:
Level the sand of your beach area―fill holes and stomp down sandcastles before you head home from a beach day, because holes can trap turtles and mounds can deter them from nesting
Place trash in designated bins, especially plastics such as straws, bottles and broken beach toys, which can all make their way into the water and be consumed by all manner of sea life.
Do not disturb turtles or their nests, including not using bright lights at night or before dawn while traversing the beach.
While boating, be mindful of speed along the coastline as turtles are harder to spot than dolphins or pelicans.
While fishing in the ocean, know that a bated hook may attract turtles and can snag them. Call DNR if this happens as hook removal could require a turtle being taken to the Georgia Sea Turtle Center on Jekyll Island.
Zemaitis underscored the need for humans to mind their consumption. "Even if you live far from the coast and don't think you have impact," she said, stressing that tons of trash and non-biodegradable items wind up in the ocean. She shared an example of balloons found in the Atlantic that had been tracked back to Alabama.
Should any early morning or late night beachgoer come across a gravid turtle or the remnants of its nesting excursion, conservationists encourage the public to contact a local sea turtle organization or Georgia DNR. Do not attempt to handle the situation yourself, especially because federal protections come with hefty fines.
Only trained professionals and volunteers with proper credentials should be interacting with turtles and their nests.
On June 6, Tammy Smith, a Tybee Island Maritime Academy teacher and volunteer sea turtle conservationist, found the island's sixth nest between 18th and 19th streets. (Tybee had eight nests as of this publication.) The turtle engraved the perfect parabola of a path up the shoreline, though Alley said given the incline the turtle likely laid the eggs where it tired out. When done, the turtle completed its U-shaped path back into the water leaving its babies behind forever.
Alley said turtles are resilient creatures. The act of laying 120+ eggs over a few hours is a mountainous effort seeing as how turtles need to drag their 200- to 400-pound bodies onto the shore with naught but their bellies and flippers, which cut cleanly through water but flap about on the sand.
Beyond possible human alterations to sand, Zemaitis and Alley said that conditions like sea-level rise and beach erosion present nesting challenges. Both issues lead to less real estate for nesting. Higher tide lines, particularly on Georgia's coast, mean more instances of nests being inundated, which could drown sea turtle babies within their soft, porous eggs. Erosion can cause steep beach inclines that result in turtles nesting much closer to the tide lines than might be effective for survival, which is what happened with the June 6 turtle. Erosion could also deter sea turtles altogether by making their trips ashore too exhausting to pursue. They could then return to the water where predators might wait, ready to attack a tired mother.
Smith and Alley relocated the June 6 eggs by carefully lifting them out of the initial hole and then placing them just as carefully into one Smith had pre-dug just before the dune grass. "Reptile eggs are temperature dependent with how the sexes develop," Alley said. The last eggs the turtle had laid on top were closer to the warm beach surface and therefore more likely to become female. Conversationists do not want to disrupt that natural order, so Alley explained that they move the turtle eggs by placing the top eggs from the nest at the bottom of the carrier, so that the relocation nest has eggs returned to their original birth order.
Alley and Smith then covered the new hole and placed a predator-deterring grate over it. To ensure humans do not disturb the nest by walking or riding ATV wheels over it, Alley and Smith tapped in three wooden slats, attached a written notice to one and used yellow DNR sea turtle nest tape to rope it off.
As you plan your next family or solo outing or perhaps a beach date on a Georgia barrier island, consider adjusting your timeline for a dawn stroll or a midnight walk. Be mindful of the beach rules and regulations, but enjoy the exercise and your company or lack thereof as you scan for turtles shuffling ashore.
Should you happen upon one in the late or early hours, keep your distance, observe and remain in awe, not only of nature taking its course but of how slight alterations to human behavior and awareness can help restore a natural order.
If you do not come across a sea turtle, don't worry, all manner of wildlife awaits. You could spot migrating and foraging birds of many stripes feeding upon Horseshoe, Ghost and blue grabs scuttling along the shoreline. Perhaps a coyote on the prowl for turtle eggs.
At the very least, you can walk and simply welcome the laughs of gulls, the slosh of the waves and the crunch of sand and seashells underfoot as the sun rises over parting pre-dawn clouds.
Joseph Schwartzburt is the education and workforce development reporter for the Savannah Morning News. You can reach him at JSchwartzburt@gannett.com and JoeInTheKnow_SMN on Instagram.
This article originally appeared on Savannah Morning News: How to help Georgia sea turtle conservation efforts this summer
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale
Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale

Yahoo

time13 minutes ago

  • Yahoo

Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale

AI heart failure diagnostics innovator makes it possible to catch deadly heart failure earlier by analyzing the most common heart scan in the world and proactively alerting clinicians FDA-cleared, reimbursed by Medicare, and live in top U.S. hospitals, Ultromics is now scaling nationwide to make early heart failure detection part of routine cardiac care, wherever patients get an echo Ultromics is trained on one of the largest real-world echo datasets globally and validated across 25 peer-reviewed studies, helping close one of medicine's most dangerous diagnostic gaps, where up to 64% of heart failure cases still go undetected OXFORD, England, July 31, 2025 /PRNewswire/ -- Ultromics, a pioneer in AI-driven cardiology solutions, today announced it has raised $55 million in Series C financing. The round was co-led by L&G, Allegis Capital and Lightrock, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund and Oxford University. Major U.S. health systems, including UChicago Medicine's venture investment vehicle, UCM Ventures, and UPMC Enterprises also participated in the round. Built on years of clinical study and hundreds of thousands of echo scans, Ultromics offers the first FDA-cleared, Medicare-reimbursed AI technology to help clinicians detect HFpEF and cardiac amyloidosis, two of the most elusive forms of heart failure. The company is now expanding across the U.S. to bring that capability to the hospitals and echo labs that see the highest volume of at-risk patients, aiming to make AI-enhanced diagnostics a default step in the cardiac workup. Ultromics is also expanding its pipeline to include additional cardiac conditions, new distribution channels and deeper partnerships with health systems and clinical leaders. It's a critical moment for cardiovascular care. Heart failure is rising, costs are mounting and millions of patients are still going undiagnosed, especially those with harder-to-detect forms like HFpEF and cardiac amyloidosis. In the U.S. alone, heart failure drives over $30 billion in annual healthcare costs, a number projected to exceed $70 billion by 2030. Clinicians often rely on subjective interpretation of echocardiograms, leading to missed or delayed diagnoses even when patients are actively seeking care. In fact, up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is frequently mistaken for more common forms of heart disease, leaving patients untreated until symptoms worsen or irreversible damage occurs. Ultromics addresses this diagnostic blind spot by using AI to extract hidden disease signals from standard echocardiograms, enabling earlier, more accurate detection of complex heart conditions—without requiring new hardware or disrupting clinical workflows. Its FDA-cleared EchoGo® platform supports diagnosis of HFpEF and cardiac amyloidosis. Trained and validated on one of the largest real-world echo datasets globally, EchoGo® generates real-time probability scores to help cardiologists identify high-risk patients earlier than traditional methods. EchoGo® is fully reimbursed under Medicare, making it scalable across hospitals, clinics, and health systems nationwide. "The reality is, hospitals already have the data, they just haven't had the tools to extract the more subtle diagnostic signals from it. By analyzing routine echocardiograms with AI, we're helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses," said Ross Upton, PhD, CEO and Founder, Ultromics. "We've spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis." Ultromics has already analyzed more than 430,000 echocardiograms to date. In clinical studies, EchoGo® improved the detection of HFpEF by 73.6% when compared with standard clinical risk scores. The company's latest diagnostic model for cardiac amyloidosis, validated in a global study of 18 institutions and published in the European Heart Journal, outperformed current clinical risk scores while distinguishing disease from similar conditions. "Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies," said Alastair Stewart, Head of Investments, Venture Capital, at L&G. "This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year." With growing adoption and partnerships across flagship institutions, including UChicago Medicine, University Hospitals Cleveland, Northwestern, and Mayo Clinic, Ultromics is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions like the Midwest. Its platform is helping hospitals reduce unnecessary tests, streamline workflows and initiate treatment earlier so it's more effective and less expensive. "Heart failure and cardiac amyloidosis impact millions of lives and strain healthcare systems, despite new approaches that have the potential to significantly improve patient outcomes. There is a critical need for scalable solutions that enable earlier, more accurate diagnosis and elevate the standard of care," said Umur Hursever, Partner at Lightrock. "Ultromics' AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics' mission and growing impact." Ultromics has rapidly expanded its platform capabilities and U.S. market presence during the past year. In late 2024, the company received FDA Breakthrough Device clearance for EchoGo® Amyloidosis, followed in 2025 by the launch of EchoGo® Score, a new feature that adds AI-driven probability scoring to EchoGo® Heart Failure, helping clinicians detect HFpEF with greater nuance. These clinical advances are now supported by Medicare reimbursement for both outpatient and inpatient use, strengthening Ultromics' foundation for scaled adoption across U.S. hospitals. "There's a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret," said Victor Westerlind, Managing Director at Allegis Capital. "What's exciting about Ultromics is how they're closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it's a diagnostic win that will help save lives." About Ultromics Founded out of the University of Oxford, Ultromics is redefining cardiovascular care with FDA-cleared, AI-powered tools that enhance echocardiographic diagnosis. Built in partnership with the NHS and Mayo Clinic, its EchoGo® platform helps clinicians detect complex heart diseases earlier and more accurately—using nothing more than a standard ultrasound scan. Ultromics is backed by leading investors and U.S. healthcare systems and is on a mission to transform how heart disease is diagnosed and treated. For more, visit About Lightrock Lightrock is a global investment platform committed to building a sustainable future. Operating across private and public markets, Lightrock manages over $5.5 billion in assets and invests in Europe, North America, Latin America, Asia, and Africa. Lightrock is a certified B Corp with a dedicated team of over 130 professionals working across a network of six offices For more information, visit About L&G Established in 1836, L&G is one of the UK's leading financial services groups and a major global investor, with £1.1 trillion in total assets under management (as at FY24) of which c. 44% (c. £0.5 trillion) is international. We have a highly synergistic business model, which continues to drive strong returns. We are a leading player in Institutional Retirement, in Retail Savings and Protection, and in Asset Management through both public and private markets. Across the Group, we are committed to responsible investing and dedicated to serving the long-term savings and investment needs of customers and society. About Allegis Capital Allegis Capital is an early-stage venture capital firm partnering with companies that enable digital transformation across the enterprise. The firm supports founders with hands-on guidance, operational expertise, and access to a global network of industry leaders. With a long track record of building market-defining businesses, Allegis backs the teams and platforms reshaping how work gets done. Headquartered in Palo Alto, California, Allegis has been investing in enterprise innovation for over two decades. For more information, visit Photo - - View original content to download multimedia: SOURCE Ultromics Sign in to access your portfolio

GLP-1 Agonists for Type 2 Diabetes Reduce Psoriasis, HS Risk
GLP-1 Agonists for Type 2 Diabetes Reduce Psoriasis, HS Risk

Medscape

time15 minutes ago

  • Medscape

GLP-1 Agonists for Type 2 Diabetes Reduce Psoriasis, HS Risk

TOPLINE: Treatment with glucagon like peptide 1 receptor agonist (GLP-1 RA) medications was associated with a lower risk of being diagnosed with hidradenitis suppurativa (HS) or psoriasis, in a study of patients with type 2 diabetes (T2D). METHODOLOGY: Researchers assessed 74,910 patients (mean age, 65 years; 56% women; 45% White and 23% Black individuals) with T2D from the All of Us Database between May 2018 and October 2023. Of all patients, 19.5% received GLP-1 RAs. The primary outcomes of the study were risks for HS and psoriasis, adjusted for effects on control of diabetes and weight loss. TAKEAWAY: Overall, 1601 patients had psoriasis (mean age, 68 years; 56.4% women; 62.4% White and 12.2% Black individuals), and 601 had HS (mean age, 55 years; 77.2% women; 32.9% White and 41.3% Black individuals). Patients treated with GLP-1 RAs showed a significantly lower risk for a future diagnosis of HS (adjusted odds ratio [OR], 0.61; P < .001) than those who were not treated with GLP-1 RAs. GLP-1 RA treatment was also associated with a significant reduction in the risk for a future diagnosis of psoriasis (adjusted OR, 0.41; P < .001). The average time from T2D diagnosis to a diagnosis of HS was 3.98 years and 3.44 years to a diagnosis of HS. IN PRACTICE: 'These findings support a protective effect against HS and psoriasis in patients with T2DM taking GLP-1 RAs independent of weight loss, smoking status, or glycemic control,' the study authors wrote. Based on these findings, they added, 'future research should focus on prospective studies exploring the use of GLP-1 RAs as therapeutic tools to treat HS or psoriasis, prevent disease progression, and evaluate their effect in patients without diabetes.' SOURCE: The study was led by Lauren M. Ching, Georgetown University School of Medicine, Washington, DC, and was published online on July 23, 2025, in JAAD International. LIMITATIONS: Limitations included variance in data harmonization across sites, lack of disease severity information, and selection bias. DISCLOSURES: The study did not receive any funding. One author reported receiving financial aids as an investigator, consultant, and speaker from AbbVie, BMS, Eli Lilly, and various other drug companies. All other authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

SpaceX, NASA say Crew-11 astronaut mission is 'go' for launch to ISS on July 31
SpaceX, NASA say Crew-11 astronaut mission is 'go' for launch to ISS on July 31

Yahoo

time17 minutes ago

  • Yahoo

SpaceX, NASA say Crew-11 astronaut mission is 'go' for launch to ISS on July 31

When you buy through links on our articles, Future and its syndication partners may earn a commission. CAPE CANAVERAL, Fla. — SpaceX's Crew-11 astronaut mission to the International Space Station for NASA is go for launch. When Crew-11 launches, a SpaceX Falcon 9 rocket will lift off from historic Launch Complex 39A here at NASA's Kennedy Space Center (KSC), sending a crew of four the ISS for a six-month stay. Mission managers with NASA and SpaceX all polled 'go' to proceed to count down towards a 12:09 p.m. ET (1609 GMT) launch attempt of the Crew-11 mission on Thursday (July 31). "I'm so eager to see this mission launch, but as always, we launch when we're ready. With a little luck, we'll see a launch soon, and we'll also see a crew come home soon," said Ken Bowersox, associate administrator for NASA's Space Operations Mission Directorate, during a prelaunch briefing at KSC today (July 30). "But be patient with us. Let's make sure that the vehicle is ready to go and that our team is really certain before we hit the button." The four Crew-11 astronauts will dock with the ISS some 39 hours after launch. They will be flying inside SpaceX's Crew Dragon Endeavour spacecraft, flying on its milestone sixth flight. No other Crew Dragon has flown more than four times. Steve Stich, manager of NASA's Commercial Crew Program, hailed the milestone in today's briefing. "As you know, this is a really important mission for us. It's our sixth flight of Dragon Endeavour. We worked very hard with SpaceX to complete all the reuse activities for this vehicle," Stich said. "We had certified the vehicles — the Dragons — for only five flights. Now we've completed all that work and we're really ready to go." Crew-11 consists of NASA astronaut Zena Cardman, who will serve as commander on her first trip to space. In a press briefing earlier this month, Cardman stressed how six-month stays on the ISS like the one she will embark on will help prepare NASA to send astronauts much farther into space. "Understanding how to live and work for long durations — going and staying — is a really interesting challenge, and I'm grateful that we've gotten the chance to do this — to hone our skills on the ISS, so that we can do this for longer durations on the moon," Cardman said. "The International Space Station, in my perspective, is an absolutely critical stepping stone as we think about going farther afield." Joining Cardman as mission pilot is veteran NASA astronaut Mike Fincke, making his fourth trip into space. Fincke previously trained to pilot Boeing's troubled Starliner spacecraft on its first operational mission, but was reassigned as delays and issues continue to plague the Starliner program. Alongside the two NASA astronauts are Kimiya Yui of the Japan Aerospace Exploration Agency (JAXA), making his second trip to the ISS while serving as Crew-11 mission specialist, and Oleg Platonov of Russia's space agency Roscosmos, mission specialist, making his first trip to space. Crew-11 will dock at 3 a.m. ET (0800 GMT) on Aug. 2 and will overlap with the Crew-10 astronauts for a few days to ensure a smooth handover before Crew-10 makes its way back to Earth for a splashdown in the Pacific Ocean. If all goes according to plan, the four members of Crew-11 will remain docked at the ISS for roughly six months before the next NASA astronaut rotation relieves them. The U.S. Space Force has predicted a 90% chance of favorable weather for Crew-11 at launch time. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store